Publicaciones en las que colabora con Salvador Martín Algarra (12)

2023

  1. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2561-2570

2015

  1. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

    Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236

  2. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

    Clinical Chemistry, Vol. 61, Núm. 1, pp. 297-304

  3. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma

    European Journal of Dermatology, Vol. 25, Núm. 5, pp. 392-403

  4. Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient

    International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115

2014

  1. Guidelines for biomarker testing in metastatic melanoma: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 362-373

  2. Recomendaciones para la determinación de biomarcadores en el melanoma metastásico. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia

  3. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients

    Clinica Chimica Acta, Vol. 429, pp. 168-174

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

2004

  1. ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

    British Journal of Cancer, Vol. 90, Núm. 5, pp. 1047-1052

2003

  1. Fine-needle aspiration cytology and immunocytochemistry in the diagnosis of 24 gastrointestinal stromal tumors: A quick, reliable diagnostic method

    Diagnostic Cytopathology, Vol. 28, Núm. 3, pp. 131-135

1989

  1. Pulmonary eosinophilic granuloma. Complete response after thymus hormone therapy

    Medicina Clinica, Vol. 92, Núm. 10, pp. 394